BioSpace News Archive

Avantor, Inc. announced that it has priced the initial public offering of 207,000,000 shares of its common stock at a price to the public of $14.00 per share and a concurrent public offering of 18,000,000 shares of its 6.250% Series A Mandatory Convertible Preferred Stock at a price to the public of $50.00 per share.

The trial evaluated margetuximab in patients with HER2-positive metastastic breast cancer who had already been treated with anti-HER2-targeted therapies.

The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.

Ginkgo Bioworks bought Warp Drive Bio’s genome mining platform, which includes its genome mining team, technology and database.

Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.

The plaintiffs allege that Gilead and other companies used anticompetitive tactics to keep prices artificially high for their respective HIV treatments.

The Institute of Cancer Research (ICR) in London, UK, is investing an initial £75 million to create a global center in what it is calling anti-evolution therapies for cancer.

Agios Pharmaceuticals, headquartered in Cambridge, Mass., announced that its Tibsovo (ivosidenib) hit its primary endpoint in the Phase III ClarIDHy trial in patients with cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

Financial terms of the deal were not disclosed, but Genentech aims to use Parvus’ technology to target IBD and Celiac.